Aitana Calvo

2.1k total citations
45 papers, 383 citations indexed

About

Aitana Calvo is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Aitana Calvo has authored 45 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 11 papers in Cancer Research and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Aitana Calvo's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Genetic factors in colorectal cancer (6 papers). Aitana Calvo is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Genetic factors in colorectal cancer (6 papers). Aitana Calvo collaborates with scholars based in Spain, United States and France. Aitana Calvo's co-authors include Antonio Portolés, G. Resplandy, Ignacio Martínez, Pilar García‐Alfonso, Andrés J. Muñoz Martín, Leonor Laredo, Miguel Martín, Patrick Schöffski, Andrew Weickhardt and María Ochoa de Olza and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Aitana Calvo

37 papers receiving 362 citations

Peers

Countries citing papers authored by Aitana Calvo

Since Specialization

Citations

This map shows the geographic impact of Aitana Calvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aitana Calvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aitana Calvo more than expected).

Fields of papers citing papers by Aitana Calvo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aitana Calvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aitana Calvo. The network helps show where Aitana Calvo may publish in the future.

Co-authorship network of co-authors of Aitana Calvo

This figure shows the co-authorship network connecting the top 25 collaborators of Aitana Calvo. A scholar is included among the top collaborators of Aitana Calvo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aitana Calvo. Aitana Calvo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation 2025 ·Annals of Oncology ·Michael B. Foote, Jingjing Li, Daniel Shao-Weng Tan, Aitana Calvo, Rachel Galot, Elena Garralda, Tormod Kyrre Guren, Antoine Italiano, (unknown), Zev A. Wainberg, Jeffrey Yachnin, Timothy A. Yap, Ruben de Kanter, Nuno Grande, (unknown), Dragana Janković, Laurent Sansregret, Chao Zhang, Ankur K. Nagaraja, Yasutoshi Kuboki	0
2	Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial. 2025 ·Journal of Clinical Oncology ·Sebastian Ochsenreither, Geòrgia Anguera, Sebastian M. Dieter, Nikolaos A. Trikalinos, (unknown), (unknown), Aitana Calvo, So Yeon Kim, Laura Rodríguez, Kaja C. G. Berg, (unknown), Anders Rosholm, Agnete B. Fredriksen, (unknown)	0
3	Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies 2022 ·Cancer Research ·Siqing Fu, Udai Banerji, Philippe L. Bédard, Aitana Calvo, Alberto Chiappori, Jayesh Desai, Rahima Jamal, (unknown), Noboru Yamamoto, Érica Leandro Marciano Vieira, Gabrielle S. Wong, Kulandayan K. Subramanian, Shunguang Wang, Britta Mueller, (unknown), Si‐Lin Koo	6
4	Analysis of survival trends, clinical, and molecular characteristics of patients with early-onset colorectal cancer (EOCRC). 2022 ·Journal of Clinical Oncology ·Javier Soto, (unknown), (unknown), (unknown), (unknown), (unknown), Manuel Alva Bianchi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrés J. Muñoz Martín, Aitana Calvo, (unknown), (unknown), (unknown), Miguel Martín, Pilar García‐Alfonso	2
5	Clinical evolution after surgery of hepatic metastases of colorectal cancer according to genomic profile. 2022 ·Journal of Clinical Oncology ·(unknown), Manuel Alva Bianchi, Andrés J. Muñoz Martín, Aitana Calvo, (unknown), (unknown), Montserrat Blanco-Codesido, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Pilar García‐Alfonso	0
6	Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study 2021 ·ESMO Open ·Roberto Bordonaro, Aitana Calvo, A. Auriemma, Antoine Hollebecque, Gábor Rubovszky, Mark Saunders, Zsuzsanna Pápai, Gerald W. Prager, Alexander Stein, Thierry André, Guillem Argilés, Antonio Cubillo, Laëtitia Dahan, Julien Edeline, (unknown), Valérie Cattan, Ronan Fougeray, Nadia Amellal, Josep Tabernero	11
7	Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study 2020 ·Clinical & Translational Oncology ·Pilar García‐Alfonso, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ágatha Martín, (unknown), Aitana Calvo, Miguel Martín	3
8	Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain 2020 ·Clinical & Translational Oncology ·Álvaro Rodríguez-Lescure, Francisco Ayala, Enrique Aranda, Aitana Calvo, Enriqueta Felip, Pilar Garrido, Ruth Vera	11
9	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer 2019 ·European Journal of Cancer ·Guillem Argilés, Thierry André, Antoine Hollebecque, Aitana Calvo, Laëtitia Dahan, Andrés Cervantes, Catherine Leger, Nadia Amellal, Ronan Fougeray, Josep Tabernero	8
10	First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 2019 ·BMC Cancer ·Alfredo Carrato, Manuel Benavides, Bartomeu Massutí, (unknown), Pilar Alfonso, E. Falcó, Margarita Reboredo, (unknown), Javier Gállego, José María Viéitez, Laura Layos, Antonieta Salud, (unknown), E. Dotor, (unknown), Mercedes Rodríguez-Garrote, Aitana Calvo, Enrique Grande, Enrique Aranda	12
11	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors 2018 ·Annals of Oncology ·Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz, Antonio Calles, José Luis Perez‐Gracia, (unknown), Sara López‐Tarruella, Mariano Ponz‐Sarvisé, Rosa Álvarez, Ainara Soria, (unknown), Javier Machín Gayarre, M. Ángela Aznar, Aitana Calvo, Pedro P. López‐Casas, Dominique Tersago, Marisol Quintero, Salvador Martín‐Algarra, Miguel Martín, Ignacio Melero	7
12	A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318). 2018 ·Journal of Clinical Oncology ·J. Randolph Hecht, Aleix Prat, Miklos Pless, Antonio Cubillo, Aitana Calvo, Steven S. Raman, Jason Chesney, Chunxu Liu, Emily Chan	7
13	Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. 2018 ·Journal of Clinical Oncology ·David S. Hong, Patrick Schöffski, Aitana Calvo, John Sarantopoulos, María Ochoa de Olza, Richard D. Carvajal, Amy Prawira, Chrisann Kyi, Taito Esaki, Wallace Akerley, Filippo de Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, (unknown), Catherine Sabatos-Peyton, Eunice L. Kwak, Daniel Shao-Weng Tan	61
14	Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC). 2018 ·Journal of Clinical Oncology ·Antoine Hollebecque, Aitana Calvo, Thierry André, Guillem Argilés, Andrés Cervantes, Catherine Leger, (unknown), Nadia Amellal, Ronan Fougeray, Josep Tabernero	4
15	Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients 2017 ·Annals of Oncology ·(unknown), Aitana Calvo, Sara López‐Tarruella, Rosa Álvarez, Yolanda Jerez, Iván Márquez‐Rodas, Sara Ramírez, Andrés J. Muñoz Martín, Antonio Calles, (unknown), (unknown), Antoni C. Picornell, (unknown), (unknown), (unknown), Tatiana Massarrah, M. Martín Jiménez	0
16	Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial 2017 ·Annals of Oncology ·Iván Márquez‐Rodas, (unknown), Sara López‐Tarruella, (unknown), (unknown), Rosa Álvarez, Enrique de Miguel, Yolanda Jerez, Aitana Calvo, (unknown), Javier Machín Gayarre, Rebeca Medina, Antonio Calles, M. Ángela Aznar, Lourdes Planelles, Marisol Quintero, Salvador Martín‐Algarra, M. Martín Jiménez, Ignacio Melero	1
17	New clinical trials regulation in Spain: analysis of royal decree 1090/2015 2016 ·Clinical & Translational Oncology ·M. Martín Jiménez, Aitana Calvo, (unknown), Rosario García‐Campelo, Encarnación González‐Flores, (unknown), Montserrat Muñoz-Mateu, (unknown), Ana Santaballa Bertrán, (unknown), (unknown), Juan Antonio Virizuela Echaburu, Miguel Ángel Seguí	4
18	Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles 2012 ·Clinical & Translational Oncology ·Juan Bayo, Paula Jiménez Fonseca, Susana Hernando, Sònia Servitja, Aitana Calvo, (unknown), Estefanía García, Iria González, Maria J. de Miguel, (unknown), (unknown), Antonio Ruíz, Agustí Barnadas	31
19	Lack of Pharmacokinetic Interaction Between Omeprazole or Lansoprazole and Ivabradine in Healthy Volunteers: An Open‐Label, Randomized, Crossover, Pharmacokinetic Interaction Clinical Trial 2006 ·The Journal of Clinical Pharmacology ·Antonio Portolés, Aitana Calvo, (unknown), Leonor Laredo, G. Resplandy, (unknown), (unknown)	31
20	Effects of Hypericum perforatum on Ivabradine Pharmacokinetics in Healthy Volunteers: An Open‐Label, Pharmacokinetic Interaction Clinical Trial 2006 ·The Journal of Clinical Pharmacology ·Antonio Portolés, (unknown), Aitana Calvo, Ignacio Martínez, G. Resplandy	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact